First-in-human study of DCY636 in healthy volunteers and patients with moderate to severe atopic dermatitis

Phase 1, randomised, double-blind trial of DCY636 in atopic dermatitis (AD) (14 cohorts), sponsored by Novartis. Primary endpoints: Incidence of adverse events and serious adverse events (Part 1) and Incidence of adverse events and serious adverse events (Part 2). Planned start Jun 2026; status: not yet recruiting.